Skip to main content
    B

    Bioatla Inc (BCAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.30
    +0.02 (+1.56%)

    Market Cap: $2.89M

    Last updated: Oct 14, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(14/23)
    Avg Surprise
    -82.86%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 6
    		$0.14N/A+101.65%Beat+145.2%
    Mar 26
    Reported May 15
    		$-4.22$-0.20-2012.35%Miss+67.5%
    Dec 25
    Reported Mar 31
    		$0.00N/A+100.00%Beat+100.0%
    Sep 25
    Reported Nov 13
    		$-13.50$-14.83+8.97%Beat-22.7%
    Jun 25
    Reported Aug 7
    		$-0.31$-0.29-6.90%Miss+98.6%
    Mar 25
    Reported May 6
    		$-13.00$-14.67+11.38%Beat+45.8%
    Dec 24
    Reported Mar 27
    		$-0.30$-0.38+21.05%Beat+46.5%
    Sep 24
    Reported Nov 7
    		$-11.00$-18.50+40.54%Beat+68.6%
    Jun 24
    Reported Aug 8
    		$-22.00$-23.00+4.35%Beat+41.3%
    Mar 24
    Reported May 14
    		$-24.00$-27.12+11.50%Beat+17.2%
    Dec 23
    Reported Mar 26
    		$-0.56$-0.79+29.04%Beat+11.0%
    Sep 23
    Reported Nov 7
    		$-35.00$-39.87+12.21%Beat-1.4%
    Jun 23
    Reported Aug 1
    		$-37.50$-32.10-16.82%Miss+2.6%
    Mar 23
    Reported May 11
    		$-29.00$-31.20+7.05%Beat+10.8%
    Dec 22
    Reported Mar 23
    		$-0.63$-0.70+10.00%Beat-1.6%
    Sep 22
    Reported Nov 4
    		$-34.50$-40.80+15.44%Beat+1.0%
    Jun 22
    Reported Aug 9
    		$-38.50$-33.83-13.80%Miss+14.4%
    Mar 22
    Reported May 5
    		$-32.50$-31.50-3.17%Miss-16.1%
    Dec 21
    Reported Mar 1
    		$-0.62$-0.63+1.59%Beat+58.7%
    Sep 21
    Reported Nov 15
    		$-34.85$-22.83-52.65%Miss-4098.8%
    Jun 21
    Reported Aug 13
    		$-45.00$-28.00-60.71%Miss-
    Mar 21
    Reported May 12
    		$-28.00$-23.00-21.74%Miss-
    Dec 20
    Reported Mar 25
    		$-1.50$-0.78-92.31%Miss-
    Sep 20
    Reported Dec 17
    		$-0.83$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.07EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin3.49%
    ROE-814.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio0.20xQuick Ratio0.20x
    Trading Statistics
    Beta0.70Avg Volume17.00K
    52-Week High$71.5052-Week Low$1.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.37
    SMA 20$1.49
    SMA 50$2.09
    SMA 200$6.37
    EMA 10$1.38
    EMA 20$1.50
    EMA 50$2.04
    EMA 200$7.59

    MACD

    Line: -0.19Signal: -0.22Hist: 0.03

    ADX

    ADX: 15.6+DI: 21.1-DI: 17.3

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down8.0
    PSAR$2.19

    Bollinger Bands

    Upper Band$1.92
    Lower Band$1.06
    %B Position5738%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    40.4

    Momentum Oscillators

    Stoch %K15.0
    Stoch %D24.5
    Williams %R-81.7
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)-90.1
    MFI (14d)43.9

    Volatility Measures

    ATR (14d)$0.30(22.7%)
    StdDev (20d)0.21
    Hist Vol134.1%(High)

    Volume Flow

    VWAP$1.28
    OBV-43.6M
    AD Line227.3B
    CMF (20d)0.125

    Volume Metrics

    Avg Vol (20d)12.9K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.63

    Pivot Points

    R3$1.29
    R2$1.29
    R1$1.28
    Pivot Point$1.28
    S1$1.27
    S2$1.27
    S3$1.26

    Advanced Oscillators

    TSI-18.61
    Ultimate Osc54.4
    KST-232.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$6.50M$0$2.00M$0$0$0$0$11.00M$0$0$1.71M$0
    Cost of Revenue$0$0$-806,000$0$0$0$11.65M$0$0$0$368,000$0
    Gross Profit$6.50M$0$2.00M$0$0$0$-11,650,000$11.00M$0$0$-368,000$0
    Operating Expenses$6.27M$9.33M$11.26M$13.79M$18.65M$17.61M$16.24M$22.27M$21.97M$24.46M$28.54M$35.02M
    R&D$3.34M$4.58M$8.00M$9.54M$13.68M$12.36M$11.65M$16.39M$16.20M$18.85M$22.67M$28.40M
    SG&A$2.93M$4.75M$3.26M$4.25M$4.96M$5.26M$4.59M$5.88M$5.77M$5.61M$5.86M$6.62M
    Operating Income$227,000$-9,308,000$-9,255,000$-13,789,000$-18,647,000$-17,614,000$-16,244,000$-11,270,000$-21,972,000$-24,457,000$-28,536,000$-35,020,000
    Interest Income$16,000$37,000$77,000$133,000$233,000$400,000$554,000$692,000$900,000$1.22M$1.64M$1.73M
    Interest Expense$0$0$532,000$1.99M$64,000$0$0$0$0$0$0$0
    Income Before Tax$452,000$-6,307,000$-9,787,000$-15,775,000$-18,711,000$-15,334,000$-14,884,000$-10,586,000$-21,072,000$-23,234,000$-26,925,000$-33,325,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$452,000$-6,344,000$-9,784,000$-15,778,000$-18,711,000$-15,334,000$-14,884,000$-10,586,000$-21,072,000$-23,234,000$-26,925,000$-33,325,000
    EBITDA$436,000$-6,224,000$-9,845,000$-15,852,000$-18,829,000$-15,551,000$-15,210,000$-11,050,000$-21,743,000$-24,217,000$-28,195,000$-34,789,000
    EBIT$436,000$-6,344,000$-9,864,000$-15,908,000$-18,944,000$-15,734,000$-15,438,000$-11,278,000$-21,972,000$-24,457,000$-28,563,000$-35,059,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BCAB

    News

    BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary

    BioAtla, Inc. reported second-quarter 2026 results, showing revenue of $6.5 million and diluted EPS of $0.27, a significant improvement from the prior year's net loss and zero revenue. The company is undergoing...

    TradingView•8/13/26•Somewhat-Bullish

    Bioatla Inc (BCAB) Stock News Today

    This article provides an update on Bioatla Inc (BCAB) stock news, earnings, analyst ratings, and key developments. As of August 7th, BCAB closed at $3.460...

    TradingKey•8/7/26•Neutral

    Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Bioatla Inc (BCAB) has an earnings forecast score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Analysts have a consensus price target of USD 10.00 and a "Strong Buy" rating for the stock....

    TradingKey•8/7/26•Bullish

    BCAB Q2'26 Earnings: EPS estimate is (8.50) USD

    BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6th. Analysts estimate revenue to be $0 with an earnings per share (EPS) of ($8.50). This report provides a quick overview of estimated vs....

    TradingView•8/5/26•Somewhat-Bearish

    BCAB Q2'26 Earnings: revenue estimate is 0 USD

    BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6, 2026, at 8:00 AM ET (12:00 PM UTC). The company's revenue estimate for the quarter is $0 USD...

    TradingView•7/30/26•Neutral

    BCAB Valuation and Fair Value

    P/E
    -0.1x
    P/B
    -0.1x
    See GNG's fair value

    BCAB Profitability: Margins, ROIC and FCF

    Operating margin
    3.5%
    Net margin
    0.0%
    ROE
    -814.0%
    FCF margin
    -276.3%

    BCAB Competitors

    CompanyTicker
    Onconetix IncONCO
    Revelation Biosciences IncREVB
    Ridgetech, Inc.RDGT
    Painreform LtdPRFX
    XORTX Therapeutics IncXRTX
    HCW Biologics IncHCWB
    GRI Bio Inc.GRI
    INVO Fertility, Inc.IVF

    Sector: Healthcare

    BCAB Bull Case vs Bear Case

    Bull case

    • BCAB beat EPS estimates in 75.0% of its last 8 reported quarters.
    • BCAB grew quarterly revenue 31.6% year over year.

    BCAB Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    39.5%

    Frequently Asked Questions About BCAB

    Does BCAB pay dividends?

    Bioatla Inc (BCAB) does not currently pay a regular dividend.

    What is BCAB's market cap?

    Bioatla Inc (BCAB) has a market capitalization of $2.89M with a current stock price of $1.30.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In